Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OPK 
Opko Health Inc (OPK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: OPK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.56
1 Year Target Price $3.56
| 2 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.13% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.06B USD | Price to earnings Ratio - | 1Y Target Price 3.56 |
Price to earnings Ratio - | 1Y Target Price 3.56 | ||
Volume (30-day avg) 7 | Beta 1.34 | 52 Weeks Range 1.11 - 2.04 | Updated Date 12/6/2025 |
52 Weeks Range 1.11 - 2.04 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.1% | Operating Margin (TTM) -35.29% |
Management Effectiveness
Return on Assets (TTM) -6.15% | Return on Equity (TTM) -13.32% |
Valuation
Trailing PE - | Forward PE 64.52 | Enterprise Value 1016618728 | Price to Sales(TTM) 1.66 |
Enterprise Value 1016618728 | Price to Sales(TTM) 1.66 | ||
Enterprise Value to Revenue 1.58 | Enterprise Value to EBITDA 22.49 | Shares Outstanding 767701280 | Shares Floating 347991313 |
Shares Outstanding 767701280 | Shares Floating 347991313 | ||
Percent Insiders 48.71 | Percent Institutions 26.14 |
Upturn AI SWOT
Opko Health Inc
Company Overview
History and Background
Opko Health Inc. was founded in 2007 by Phillip Frost, M.D. The company has evolved through a series of acquisitions and strategic partnerships, focusing on developing and commercializing diagnostics and pharmaceuticals. A significant milestone was the acquisition of Bio-Reference Laboratories in 2015, which bolstered its diagnostic capabilities.
Core Business Areas
- Diagnostics: Opko's diagnostics segment, primarily through its subsidiary Bio-Reference Laboratories, offers a broad range of laboratory testing services. This includes routine testing, advanced genetic testing, oncology testing, and infectious disease testing. They serve physicians, hospitals, and other healthcare providers.
- Pharmaceuticals: The pharmaceutical segment focuses on the development and commercialization of innovative drug products. Their pipeline includes therapies for various conditions, with a particular emphasis on urology and women's health.
- Medical Devices: Opko also develops and markets medical devices, often in conjunction with its pharmaceutical products, to enhance treatment delivery and patient outcomes.
Leadership and Structure
Opko Health Inc. is led by its Chairman and CEO, Phillip Frost, M.D. The company operates through its various subsidiaries, including Bio-Reference Laboratories, Inc., and has a divisional structure aligned with its core business areas.
Top Products and Market Share
Key Offerings
- Product Name 1: Rayaldee (calcifediol extended-release capsules) - Used for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Competitors include various vitamin D supplements and other treatments for SHPT. Market share data is not readily available publicly but is a key product for their pharmaceutical segment.
- Product Name 2: Bio-Reference Laboratories Testing Services - This is not a single product but a suite of diagnostic tests covering a wide array of medical conditions. As a major clinical laboratory, Bio-Reference competes with other large diagnostic laboratories like Quest Diagnostics and LabCorp. Their market share is significant within the clinical diagnostics industry, serving millions of patients.
Market Dynamics
Industry Overview
Opko Health operates within the dynamic and highly regulated healthcare industry, encompassing diagnostics and pharmaceuticals. The diagnostics market is driven by advancements in technology, increasing demand for personalized medicine, and a growing focus on preventative care. The pharmaceutical market is characterized by intense competition, patent expirations, and the long, expensive process of drug development and approval.
Positioning
Opko Health is positioned as a diversified healthcare company with a dual focus on diagnostics and pharmaceutical development. Its acquisition of Bio-Reference Laboratories gives it a strong footing in the clinical diagnostics market, providing a steady revenue stream. Its pharmaceutical segment offers potential for growth through its pipeline of novel therapies.
Total Addressable Market (TAM)
The TAM for clinical diagnostics is in the hundreds of billions of dollars globally, driven by an aging population, rising chronic disease prevalence, and technological innovation. The TAM for pharmaceuticals is in the trillions of dollars. Opko Health, through Bio-Reference, has a significant share in a segment of the diagnostics TAM. Its pharmaceutical products target specific niches within the broader pharmaceutical TAM, with the potential to grow substantially if pipeline products are successful.
Upturn SWOT Analysis
Strengths
- Diversified business model with both diagnostics and pharmaceuticals.
- Strong market presence in clinical diagnostics through Bio-Reference Laboratories.
- Experienced leadership team with a background in healthcare and business.
- Potential for growth in its pharmaceutical pipeline.
Weaknesses
- Reliance on successful clinical trial outcomes for pharmaceutical products.
- Significant debt load from acquisitions.
- Dependence on reimbursement rates from government and private payers.
- Execution risk in bringing new drugs to market.
Opportunities
- Expansion of diagnostic testing services into new areas like genomics and personalized medicine.
- Strategic partnerships and licensing agreements for pharmaceutical products.
- Growing demand for point-of-care diagnostics.
- Leveraging data analytics from its diagnostics business to inform pharmaceutical development.
Threats
- Intense competition in both diagnostics and pharmaceutical markets.
- Regulatory changes and government healthcare policy shifts.
- Pricing pressures from payers and competitors.
- The high failure rate of drug development.
Competitors and Market Share
Key Competitors
- Quest Diagnostics (DGX)
- LabCorp (LH)
- Thermo Fisher Scientific (TMO)
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
Competitive Landscape
Opko Health faces formidable competition in both its diagnostics and pharmaceutical segments. In diagnostics, larger, well-established players like Quest Diagnostics and LabCorp have broader reach and brand recognition. In pharmaceuticals, it competes with global giants with extensive R&D budgets and established market access. Opko's advantage lies in its integrated model and potential for niche product development, but it struggles with the scale of its larger competitors.
Major Acquisitions
Bio-Reference Laboratories, Inc.
- Year: 2015
- Acquisition Price (USD millions): 1470
- Strategic Rationale: This acquisition significantly expanded Opko's diagnostic capabilities and market reach, providing a substantial and recurring revenue stream.
Growth Trajectory and Initiatives
Historical Growth: Opko Health's historical growth has been largely driven by strategic acquisitions, particularly the acquisition of Bio-Reference Laboratories. Organic growth in its segments has varied. The company has focused on expanding its diagnostic service offerings and advancing its pharmaceutical pipeline.
Future Projections: Future growth projections for Opko Health are contingent on the success of its pharmaceutical pipeline, the continued performance of its diagnostics business, and its ability to manage its debt. Analyst estimates would provide quantitative projections, but these are subject to change.
Recent Initiatives: Recent initiatives may include the advancement of specific drug candidates through clinical trials, expansion of diagnostic capabilities, and potential strategic partnerships or divestitures.
Summary
Opko Health Inc. is a diversified healthcare company with a solid presence in the diagnostics market through Bio-Reference Laboratories and a developing pharmaceutical pipeline. Its strengths lie in its integrated business model and experienced leadership. However, it faces significant challenges from intense competition, the high costs of drug development, and a substantial debt burden. Continued success will depend on the efficacy of its drug candidates and its ability to navigate a complex regulatory and market landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Opko Health Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Stock market investments involve risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opko Health Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1995-11-02 | Chairman & CEO Dr. Phillip Frost M.D., Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2997 | Website https://www.opko.com |
Full time employees 2997 | Website https://www.opko.com | ||
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.